Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | INMT | O95050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17505097 | 1.00 | NFE2L2 (0.42) | NFE2L2NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL17505084 | 1.00 | NFE2L2 (0.42) | NFE2L2NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL17505127 | 0.83 | NFE2L2 (0.44) | NFE2L2 | |
| SCHEMBL17505128 | 0.83 | NFE2L2 (0.44) | NFE2L2 | |
| SCHEMBL17507280 | 0.83 | NFE2L2 (0.64) | NFE2L2NPC1 | |
| SCHEMBL17507307 | 0.83 | NFE2L2 (0.64) | NFE2L2NPC1 | |
| SCHEMBL17507283 | 0.81 | NFE2L2 (0.48) | NFE2L2 | |
| SCHEMBL17505114 | 0.81 | NFE2L2 (0.45) | NFE2L2SMN1; SMN2 | |
| SCHEMBL22005138 | 0.81 | NFE2L2 (0.49) | NFE2L2 | |
| SCHEMBL17505112 | 0.81 | NFE2L2 (0.45) | NFE2L2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11129819-B2 | Fumarate analogs and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200155531-A1 | Fumarate Analogs and Uses Thereof | MIDCAP FINANCIAL TRUST | 2020-05-21 | — | — | US | disclosed |
| US-20180071271-A1 | Fumarate Analogs and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-03-15 | — | — | US | disclosed |
| US-9801866-B2 | Fumarate analogs and uses thereof | Rigl Pharmaceutical, Inc. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-3177599-A1 | FUMARATE ANALOGS AND USES THEREOF IN THE TREATMENT OF AN AUTOIMMUNE DISEASE OR AN INFLAMMATORY DISEASE | Rigel Pharmaceuticals, Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20170065569-A1 | Fumarate Analogs and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-03-09 | — | — | US | disclosed |
| WO-2016022434-A1 | FUMARATE ANALOGS AND USES THEREOF IN THE TREATMENT OF AN AUTOIMMUNE DISEASE OR AN INFLAMMATORY DISEASE | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071271-A1 | Fumarate Analogs and Uses Thereof | FH, GLS, FPGS | NFE2L2 205/4885NPC1 3833/4885HPGD 114/4885 |
| US-20200155531-A1 | Fumarate Analogs and Uses Thereof | FH, GLS, FPGS | NFE2L2 205/4885NPC1 3833/4885HPGD 114/4885 |
| US-11129819-B2 | Fumarate analogs and uses thereof | FH, GLS, FPGS | NFE2L2 205/4885NPC1 3833/4885HPGD 114/4885 |
| US-20170065569-A1 | Fumarate Analogs and Uses Thereof | FH, GLS, FPGS | NFE2L2 205/4885NPC1 3833/4885HPGD 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.